Nearly half of the 50+ Immuno-Oncology Clinical Trials that CGI is supporting are Combination trials involving multiple oncology drugs. CGI expects enrollment of over 4,500 patients into these combination Immuno-Oncology trials with leading pharma and biotech companies globally. RUTHERFORD, N.J. and LOS ANGELES, Sept. 20, 2017 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (“CGI” or the “Company”) (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today it has closed its 25th contract to support a drug combination trial for immuno-oncology agents. These combination trials are with leading pharmaceutical or biotech companies and are focused on […]